PanTher Therapeutics, LLC competitors & alternatives

Shattuck Labs, Inc.STTK · BiotechAustin, United States

69% matchPublic

Biotech

Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.

Ollin BioBiotechnologyUnited States

69% match

Biotechnology

Ollin Biosciences is a clinical-stage biopharmaceutical holding company established in 2023 and headquartered in Austin, Texas, dedicated to developing therapeutics.

Biotechnology

Mati Therapeutics Inc. is a development-stage company headquartered in Austin, Texas, focused on developing therapeutic products.

Quanta Therapies, Inc.BiotechnologyUnited States

68% matchPrivate

Biotechnology

Quanta Therapies is a biopharmaceutical company that develops allosteric small molecule inhibitors targeting RAS-driven cancers, such as pancreatic, colorectal, lung, and endometrial cancers. The company focuses on modulating RAS signaling at the cell membrane to treat previously undruggable mutations like KRAS G12D and KRAS G12V.

January Therapeutics, Inc.HealthtechUnited States

67% matchPrivate

Healthtech

January Therapeutics, Inc. is a privately held biotechnology company founded in 2017 and based in California, focused on developing next-generation targeted anti-cancer therapies.

Biotech

Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to advance and commercialize NanoTx's treatment for glioblastoma. Founded in 1996 and headquartered in Austin, Texas, the firm adopted its current name, Plus Therapeutics, Inc., in July 2019, having previously operated as Cytori Therapeutics, Inc.

Biotech

Panther Life Sciences is a privately held biotechnology company founded in 2023 and headquartered in New York, NY. The company licenses and develops new treatments utilizing dissolvable microarray patch (MAP) technology to deliver shelf-stable medicine through the skin.

Biotech

NeuroX1 Inc. is a for-profit biotechnology startup founded in 2021 with headquarters in Austin, Texas, operating a target identification and drug discovery platform that utilizes proprietary technology.

Pan Cancer TBiotechnologyNetherlands

67% match

Biotechnology

Pan Cancer T develops pioneering T-cell receptor (TCR-T) cell therapies designed to empower patients' immune systems to target and overcome solid tumors. The company utilizes proprietary gene engineering to enhance T-cell fitness and persistence against unique cancer-specific intracellular targets.

Duo Oncology Inc.BiotechnologyUnited States

67% matchPrivate

Biotechnology

Duo Oncology Inc. is a United States-based company located in Pittsburgh, Pennsylvania, specializing in stroma-penetrating nanomedicine to improve cancer treatments.

BlossomHill Therapeutics, Inc.BLSM · BiotechSan Diego, United States

66% matchPublic

Biotech

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

Biotech

Propanc Biopharma, Inc. (PPCB) is an Australian biopharmaceutical firm dedicated to developing innovative treatments for various cancers, with a particular focus on pancreatic, ovarian, and colorectal malignancies. The company's leading therapeutic candidate, PRP, is a unique formulation currently in the preclinical stage of development. This product is designed to enhance the effectiveness of multiple enzymes that work together to combat cancer. Propanc Biopharma is also engaged in a collaborative research effort with the University of Jaén, initiating the POP1 joint drug discovery program. Founded in 2007, the entity was originally known as Propanc Health Group Corporation before officially changing its name to Propanc Biopharma, Inc. in April 2017. The company's headquarters are located in Camberwell, Australia.